Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company MorphoSys AG
DescriptionHuman IgG1 mAb against IL-17C developed using Ylanthia antibody technology
Molecular Target Interleukin-17C (IL-17C)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard Indication Inflammation (unspecified)
Indication DetailsTreat inflammatory diseases
Regulatory Designation
PartnerGalapagos N.V.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today